Company: HQL
Filing Date: 2025-06-09
Form Type: N-CSRS
Source: 0001104659-25-057746
Chunk: 8

Company: abrdn Life Sciences Investors
Filing Date: 2025-06-09
Form: N-CSRS
Chunk 8
---
,570 |
| Average net assets applicable to common shareholders (000 omitted)                |    $439,717 |     $433,142 |                                 $421,289 | $436,937 | $519,380 | $449,677 |
| Gross operating expenses                                                          |    1.25%(e) |        1.36% |                                    1.35% |    1.38% |    1.24% |    1.22% |
| Net Investment loss                                                               |   -0.63%)(e |       -0.44% |                                   -0.52% |   -0.68% |   -0.80% |   -0.47% |
| Portfolio turnover                                                                |      38%(f) |          46% |                                      35% |      42% |      62% |      51% |

| (a) 
 (b) | Effective October 27, 2023, abrdn Inc. became the investment adviser of the Fund. Prior to October 27, 2023, the Fund was managed by Tekla Capital Management, LLC. Members of the portfolio management           
 team from Tekla joined abrdn Inc., and continue to manage the Fund.                                                                                                                                               
 Beginning with the year ended September 30, 2023, the Fund’s financial statements were audited by KPMG LLP.                                                                                                       
 Previous years were audited by a different independent registered public accounting firm.                                                                                                                         |
|:----|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (c) | Based on average shares outstanding.                                                                                                                                                                              |
| (d) | Total investment return based on market value is calculated assuming that shares of the Fund’s common stock were purchased at the closing market price as of the beginning of the period, dividends,              
 capital gains and other distributions were reinvested as provided for in the Fund’s dividend reinvestment plan and then sold at the closing market price per share on the last day of the period. The computation 
 does not reflect any sales commission investors may incur in purchasing or selling shares of the Fund. The total investment return based on the net asset value is similarly computed except that the Fund’s net  
 asset value is substituted for the closing market value.                                                                                                                                                          |
| (e) |                                                                                                                                                                                                                   |

| abrdn Life Sciences Investors | 13 |

Financial Highlights (concluded)

| (f) | Not annualized. |

Amounts listed as “–